Stockscreener 앱 받기
13.12
3.67%
-0.50
시간 외 거래:
13.12
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
How to Take Advantage of moves in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq L - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc [NASDAQ: VRDN] Sees Increase in Stock Value - knoxdaily.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Viridian Therapeutics Inc (VRDN) did well last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Upward Trajectory: Viridian Therapeutics Inc (VRDN) Posts a Gaine, Closing at 13.53 - DWinneX
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70 - Defense World
HC Wainwright Reiterates Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Inc [VRDN] Shares Fall -1.82 % on Wednesday - knoxdaily.com
How did Viridian Therapeutics Inc (VRDN) fare last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
Sector Update: Health Care - TradingView
Graves Ophthalmopathy Therapeutics Market Size in 7MM - openPR.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Lifted by Vanguard Group Inc. - Defense World
American Century Companies Inc. Has $2.18 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
KLP Kapitalforvaltning AS Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Appoints Jeff Ajer To Board - citybiz
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - BioSpace
Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks
Viridian Therapeutics appoints Jeff Ajer to board - Investing.com
Viridian Therapeutics appoints Jeff Ajer to board By Investing.com - Investing.com UK
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Corebridge Financial Inc. - Defense World
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com Canada
(VRDN) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World
Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World
Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World
410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World
Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK
Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa
Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq
Viridian Therapeutics appoints new director, sees board resignation - Investing.com India
0.39%
3.66%
자본화:
|
볼륨(24시간):